Oxodolinum
Oxodolinum Uses, Dosage, Side Effects, Food Interaction and all others data.
Chlortalidone prevents reabsorption of sodium and chloride by inhibiting the Na+/Cl− symporter in the distal convoluted tubule. Thiazides and related compounds also decrease the glomerular filtration rate, which further reduces the drug's efficacy in patients with kidney impairment (e.g. kidney insufficiency). By increasing the delivery of sodium to the distal renal tubule, chlortalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism (i.e. apical ROMK/Na channels coupled with basolateral NKATPases). This can result in hypokalemia and hypochloremia as well as a mild metabolic alkalosis; however, the diuretic efficacy of chlortalidone is not affected by the acid-base balance of the patient being treated.
Initially, diuretics lower blood pressure by decreasing cardiac output and reducing plasma and extracellular fluid volume. Eventually, cardiac output returns to normal, and plasma and extracellular fluid volume return to slightly less than normal, but a reduction in peripheral vascular resistance is maintained, thus resulting in an overall lower blood pressure. The reduction in intravascular volume induces an elevation in plasma renin activity and aldosterone secretion, further contributing to the potassium loss associated with thiazide diuretic therapy.
Trade Name | Oxodolinum |
Availability | Prescription only |
Generic | Chlorthalidone |
Chlorthalidone Other Names | Chlorphthalidolone, Chlortalidone, Chlortalidonum, Chlorthalidone, Clortalidona, Phthalamodine, Phthalamudine |
Related Drugs | amlodipine, lisinopril, metoprolol, losartan, furosemide, hydrochlorothiazide, spironolactone, Lasix, torsemide, bumetanide |
Type | |
Formula | C14H11ClN2O4S |
Weight | Average: 338.766 Monoisotopic: 338.012805247 |
Protein binding | Approximately 75 percent of the drug is bound to plasma proteins, 58 percent of the drug being bound to albumin. This is caused by an increased affinity of the drug to erythrocyte carbonic anhydrase. |
Groups | Approved |
Therapeutic Class | Thiazide diuretics & related drugs |
Manufacturer | |
Available Country | Russia |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Oxodolinum is used for the management of hypertension. Oxodolinum is used for adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy.
Oxodolinum is also used to associated treatment for these conditions: Calcium Nephrolithiasis
How Oxodolinum works
Oxodolinum prevents reabsorption of sodium and chloride through inhibition of the Na+/Cl- symporter in the cortical diluting segment of the ascending limb of the loop of Henle. Reduction of sodium reabsorption subsequently reduces extracellular fluid and plasma volume via an osmotic, sodium-driven diuresis. By increasing the delivery of sodium to the distal renal tubule, Oxodolinum indirectly increases potassium excretion via the sodium-potassium exchange mechanism. The exact mechanism of chlorthalidone's anti-hypertensive effect is under debate, however, it is thought that increased diuresis results in decreased plasma and extracellular fluid volume which therefore requires decreased cardiac output and overall lowers blood pressure. Oxodolinum has also been shown to decrease platelet aggregation and vascular permeability, as well as promote angiogenesis in vitro, which is thought to be partly the result of reductions in carbonic anhydrase–dependent pathways. These pathways may play a role in chlorthalidone's cardiovascular risk reduction effects.
Dosage
Oxodolinum dosage
Therapy should be initiated with the lowest possible dose and then titrated according to individual patient response. A single dose given in the morning with food is recommended; divided doses are unnecessary.
Edema: Up to 50 mg daily.
Hypertension: 25 mg daily in the morning, increased to 50 mg daily if necessary.
Heart failure: 25-50 mg daily in the morning, increased if necessary to 100-200 mg daily (reduce to lowest effective dose for maintenance).
Maintenance doses may often be lower than initial doses and should be adjusted according to the individual patient.
Side Effects
Dry mouth, thirst, nausea, vomiting, feeling weak, drowsy, restless, or light-headed, fast or uneven heartbeat, muscle pain or weakness, urinating less than usual or not at all, easy bruising or bleeding, unusual weakness, red or purple spots on skin, numbness or tingly feeling, nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools.
Precaution
Renal impairment: Oxodolinum dosage should be reduced in moderate renal failure - every 24 or 48 h - and should not be used in advanced renal failure.
Liver disease: There is a risk of precipitating hepatic encephalopathy in patients with liver cirrhosis and ascites.
Use in pregnancy: It is better to avoid Oxodolinum as it crosses the placenta.
Use in Lactation: In lactating mother, significant amount of Oxodolinum enter breast milk; like other long-acting thiazides, it can suppress lactation. Oxodolinum should not be prescribed for lactating mother.
Interaction
Oxodolinum may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic peripheral adrenergic blocking drugs.
Food Interaction
- Take with food. Food may increase bioavailability.
Oxodolinum Alcohol interaction
[Moderate]
Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.
Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.
Caution and close monitoring for development of hypotension is advised during coadministration of these agents.
Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.
Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.
Oxodolinum Cholesterol interaction
[Moderate] Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.
Whether these effects are dose-related and sustained during chronic therapy are unknown.
Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen
Oxodolinum Drug Interaction
Moderate: metoprolol, metoprolol, metoprolol, metoprolol, cholecalciferol, cholecalciferolUnknown: aspirin, aspirin, aspirin, aspirin, ubiquinone, ubiquinone, apixaban, apixaban, omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid
Oxodolinum Disease Interaction
Major: anuria, electrolyte losses, liver disease, lupus erythematosus, renal function disordersModerate: asthma, diabetes, hyperlipidemia, hyperparathyroidism, hyperuricemia, thyroid function tests
Volume of Distribution
Oxodolinum has been shown to rapidly concentrate within erythrocytes and subsequently equilibrate via a slow diffusion back into the serum compartment, resulting in a large volume of distribution.
Half Life
40-50 hours
Elimination Route
Approximately 50% of the administered dose is excreted unmetabolized through the kidney, and excretion is characterized by biphasic elimination with a rapid phase followed by a slow secretory phase.
Pregnancy & Breastfeeding use
Pregnancy category B. Thiazides are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from chlorthalidone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Contraindication
Patients with anuria and known hypersensitivity to Oxodolinum or other sulfonamide-derived drugs.
Special Warning
Pediatric Use: Safety and effectiveness of Oxodolinum tablets in pediatric patients have not been established.
Geriatric Use: Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
Acute Overdose
Symptoms of acute overdosage include nausea, weakness, dizziness, and disturbances of electrolyte balance. The oral LD50 of the drug in the mouse and the rat is more than 25,000 mg/kg body weight. The minimum lethal dose (MLD) in humans has not been established. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment. Where necessary, this may include intravenous dextrose-saline with potassium, administered with caution.
Storage Condition
Store in a cool & dry place, away from children
Innovators Monograph
You find simplified version here Oxodolinum
Oxodolinum contains Chlorthalidone see full prescribing information from innovator Oxodolinum Monograph, Oxodolinum MSDS, Oxodolinum FDA label